Form 4: Cardlytics CEO Sells Shares for Tax Obligations

Cardlytics CEO Amit Gupta sold 136,945 shares of common stock to cover tax withholding obligations following the vesting of 250,000 restricted stock units.

Summary

• Cardlytics CEO Amit Gupta acquired 250,000 shares of common stock on August 18, 2025, through the vesting of restricted stock units (RSUs).
• These RSUs were part of two awards, each for 500,000 shares, granted on August 21, 2024, and January 29, 2025, respectively.
• The vesting occurred on the six-month anniversary of his CEO appointment (August 16, 2024), with 25% of each award vesting.
• To satisfy tax withholding obligations related to the RSU vesting, Mr. Gupta sold a total of 136,945 shares.
• On August 18, 2025, 68,260 shares were sold at a weighted average price of $1.125 per share, with prices ranging from $1.075 to $1.19.
• On August 19, 2025, an additional 68,685 shares were sold at a weighted average price of $1.118 per share, with prices ranging from $1.085 to $1.155.
• Following these transactions, Mr. Gupta's direct beneficial ownership of common stock is 491,759 shares.
• He also beneficially owns 250,000 unvested Restricted Stock Units from the August 21, 2024 grant and 250,000 unvested Restricted Stock Units from the January 29, 2025 grant.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions related to executive compensation. The vesting of RSUs is a positive sign of continued executive commitment, and the subsequent sales are for tax purposes, which is a neutral, expected event. There are no significant positive or negative surprises.

Positives

• The vesting of 250,000 Restricted Stock Units indicates continued employment and alignment of the CEO's interests with shareholder value.
• The sales were explicitly stated to be solely for tax withholding obligations, not for discretionary reasons, which is a common and expected practice for RSU vesting.

Negatives

• The sale of 136,945 shares, even for tax purposes, reduces the CEO's direct beneficial ownership of common stock.
• The sale prices of $1.125 and $1.118 are relatively low, reflecting the current market valuation of the shares.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide broader industry context or trends. It reflects standard compensation practices for executives involving equity awards.

Stakeholder Impact

• Shareholders: The CEO's continued equity ownership aligns his interests with shareholders, though the tax-related sales slightly reduce his direct stake. The sales themselves are small relative to total shares outstanding and are unlikely to have a material impact on the stock price.
• Employees: The RSU vesting and compensation structure may serve as a model or incentive for other employees.

Next Steps

• Remaining 50% of the RSU awards (250,000 shares from each grant) are scheduled to vest in two equal installments on the eighteenand twenty-four-month anniversaries of August 16, 2024, contingent on continued employment.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of Restricted Stock Units and subsequent sales to cover tax obligations. Such transactions are common for executives receiving equity compensation and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. The sales were explicitly for tax purposes, not discretionary. Therefore, this filing alone does not provide a basis for a "buy" or "sell" recommendation, and a "hold" stance is appropriate as it reflects a neutral event in the company's ongoing operations.

Keywords

Cardlytics, CDLX, Amit Gupta, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, CEO, Beneficial Ownership